Medidata Solutions (MDSO) Getting Somewhat Favorable Media Coverage, Study Shows

News articles about Medidata Solutions (NASDAQ:MDSO) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Medidata Solutions earned a news impact score of 0.12 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.0362169491779 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of Medidata Solutions (NASDAQ MDSO) opened at 80.01 on Friday. The firm has a market cap of $4.53 billion, a price-to-earnings ratio of 129.26 and a beta of 1.77. Medidata Solutions has a 1-year low of $46.10 and a 1-year high of $85.92. The company’s 50-day moving average is $76.67 and its 200 day moving average is $73.08.

Medidata Solutions (NASDAQ:MDSO) last issued its earnings results on Tuesday, July 18th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.03. Medidata Solutions had a net margin of 7.07% and a return on equity of 11.14%. The business had revenue of $137.41 million for the quarter, compared to analyst estimates of $134.28 million. During the same period in the previous year, the business earned $0.24 EPS. The firm’s revenue was up 19.9% on a year-over-year basis. On average, equities research analysts expect that Medidata Solutions will post $1.29 EPS for the current fiscal year.

Several brokerages have recently commented on MDSO. BidaskClub cut shares of Medidata Solutions from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Royal Bank Of Canada began coverage on shares of Medidata Solutions in a research report on Tuesday, September 19th. They set a “sector perform” rating and a $82.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price target (up previously from $75.00) on shares of Medidata Solutions in a research report on Friday, July 21st. Piper Jaffray Companies increased their price target on shares of Medidata Solutions to $87.00 and gave the stock an “overweight” rating in a research report on Friday, July 7th. Finally, J P Morgan Chase & Co increased their price target on shares of Medidata Solutions to $87.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 18th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $84.64.

TRADEMARK VIOLATION NOTICE: “Medidata Solutions (MDSO) Getting Somewhat Favorable Media Coverage, Study Shows” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://ledgergazette.com/2017/10/15/medidata-solutions-mdso-getting-somewhat-favorable-media-coverage-study-shows.html.

In other Medidata Solutions news, COO Michael L. Capone sold 5,000 shares of the business’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $74.53, for a total value of $372,650.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 5.80% of the stock is owned by insiders.

About Medidata Solutions

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Shares of Medidata Solutions (NASDAQ MDSO) opened at 80.01 on Friday. The firm has a market cap of $4.53 billion, a price-to-earnings ratio of 129.26 and a beta of 1.77. Medidata Solutions has a 1-year low of $46.10 and a 1-year high of $85.92. The company’s 50-day moving average is $76.67 and its 200 day moving average is $73.08.

Medidata Solutions (NASDAQ:MDSO) last issued its earnings results on Tuesday, July 18th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.03. Medidata Solutions had a net margin of 7.07% and a return on equity of 11.14%. The business had revenue of $137.41 million for the quarter, compared to analyst estimates of $134.28 million. During the same period in the previous year, the business earned $0.24 EPS. The firm’s revenue was up 19.9% on a year-over-year basis. On average, equities research analysts expect that Medidata Solutions will post $1.29 EPS for the current fiscal year.

Several brokerages have recently commented on MDSO. BidaskClub cut shares of Medidata Solutions from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Royal Bank Of Canada began coverage on shares of Medidata Solutions in a research report on Tuesday, September 19th. They set a “sector perform” rating and a $82.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price target (up previously from $75.00) on shares of Medidata Solutions in a research report on Friday, July 21st. Piper Jaffray Companies increased their price target on shares of Medidata Solutions to $87.00 and gave the stock an “overweight” rating in a research report on Friday, July 7th. Finally, J P Morgan Chase & Co increased their price target on shares of Medidata Solutions to $87.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 18th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $84.64.

TRADEMARK VIOLATION NOTICE: “Medidata Solutions (MDSO) Getting Somewhat Favorable Media Coverage, Study Shows” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://ledgergazette.com/2017/10/15/medidata-solutions-mdso-getting-somewhat-favorable-media-coverage-study-shows.html.

In other Medidata Solutions news, COO Michael L. Capone sold 5,000 shares of the business’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $74.53, for a total value of $372,650.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 5.80% of the stock is owned by insiders.

About Medidata Solutions

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Insider Buying and Selling by Quarter for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply